{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T17:15:10Z","timestamp":1788023710721,"version":"build-2784847793"},"reference-count":20,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Treating to absolute treatment targets rather than relative measures such as Psoriasis Area and Severity Index (PASI)\u201075 is emerging as an important clinical concept included in psoriasis guidelines and clinical practice. Achieving treatment targets is associated with achievement of long\u2010term outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the relationship between psoriasis severity, disease characteristics and achievement of PASI \u22642 with apremilast in a pooled analysis of the phase 3 ESTEEM 1 and 2 (NCT01194219 and NCT01232283), phase 3b LIBERATE (NCT01690299) and phase 4 UNVEIL (NCT02425826) clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Pooled data from patients with moderate\u2010to\u2010severe plaque psoriasis randomized to apremilast 30 mg BID were analysed by baseline PASI quartiles (Q1: 2.4\u201313.1; Q2: 13.2\u201315.9; Q3: 16.0\u201320.0; Q4: 20.1\u201357.8). Assessments included PASI, Dermatology Life Quality Index (DLQI), Scalp Physician\u2019s Global Assessment (ScPGA; ScPGA \u22651) and target (worst) Nail Psoriasis Severity Index (NAPSI; NAPSI \u22651).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1062 patients, 963 had ScPGA \u22651 and 643 had NAPSI \u22651; 771 patients with baseline and Week 32 PASI assessments were included in analyses of Week 32 PASI target achievement. Rates of PASI \u22642 at Week 32 were greater in lower PASI quartiles (Q1: 43.5%; Q2: 31.2%; Q3: 26.8%; Q4: 18.4%). Most patients achieving PASI \u22642 target (83.6%) achieved DLQI \u22645 at Week 32; 59.3% of patients who did not achieve PASI \u22642 target achieved DLQI \u22645. At Week 32, mean improvements in ScPGA and NAPSI were similar with more moderate vs. more severe disease (ScPGA, range: 1.1\u20131.4; NAPSI, range: 1.6\u20132.5). In a subgroup analysis, achievement of PASI \u22642 target was higher in the lowest PASI quartile and with disease duration &lt;5 years.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Greater achievement of PASI \u22642 was observed in patients with more moderate vs. more severe skin disease. Apremilast may be particularly beneficial in more moderate disease early in the treatment paradigm.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.17520","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T19:01:36Z","timestamp":1626202896000},"page":"2409-2414","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis"],"prefix":"10.1111","volume":"35","author":[{"given":"K.","family":"Reich","sequence":"first","affiliation":[{"name":"Center for Translational Research in Inflammatory Skin Diseases Institute for Health Services Research in Dermatology and Nursing University Medical Center Hamburg\u2010Eppendorf Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Mrowietz","sequence":"additional","affiliation":[{"name":"University Medical Center Schleswig\u2010Holstein Campus Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Menter","sequence":"additional","affiliation":[{"name":"Baylor University Medical Center Dallas TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.E.M.","family":"Griffiths","sequence":"additional","affiliation":[{"name":"The Dermatology Centre Manchester Academic Health Science Centre The University of Manchester Manchester UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bagel","sequence":"additional","affiliation":[{"name":"Psoriasis Treatment Center of Central New Jersey East Windsor NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Strober","sequence":"additional","affiliation":[{"name":"Yale University New Haven CT USA"},{"name":"Central Connecticut Dermatology Research Cromwell CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nunez Gomez","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Summit NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Shi","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Guerette","sequence":"additional","affiliation":[{"name":"Amgen Inc. Thousand Oaks CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Lebwohl","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-010-1080-1"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18333"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2017.1395794"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.10.017"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2013.04.003"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.03.049"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14164"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14015"},{"issue":"8","key":"e_1_2_7_11_1","first-page":"801","article-title":"Efficacy and safety of apremilast in patients with moderate plaque psoriasis with lower BSA: week 16 results from the UNVEIL study","volume":"16","author":"Strober B","year":"2017","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16431"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0022-202X.2005.23621.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3331"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2833"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17403"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-0851"},{"key":"e_1_2_7_18_1","unstructured":"IversenL PaulC CirulliJ ChenR AnderssonC YamauchiP.Efficacy of apremilast versus placebo in patients with lower plaque psoriasis disease activity: Results of a pooled post hoc analysis of the ESTEEM 1 and 2 trials [poster P1957]. Presented at: Annual Meeting of the European Academy of Dermatology and Venereology; September 13\u201017 2017; Geneva Switzerland."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00367-x"},{"key":"e_1_2_7_20_1","first-page":"1","article-title":"Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate\u2010to\u2010severe plaque psoriasis: results from a European, multicentric, retrospective, real\u2010world study","author":"Chiricozzi A","year":"2019","journal-title":"J Dermatol Treat"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1746734"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17520","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17520","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:38:28Z","timestamp":1692963508000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10.1111\/jdv.17520"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17520","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"assertion":[{"value":"2021-02-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}